[go: up one dir, main page]

WO2005112999A3 - Traitement du cancer au moyen d'inhibiteurs de synthese du collagene - Google Patents

Traitement du cancer au moyen d'inhibiteurs de synthese du collagene Download PDF

Info

Publication number
WO2005112999A3
WO2005112999A3 PCT/US2005/017732 US2005017732W WO2005112999A3 WO 2005112999 A3 WO2005112999 A3 WO 2005112999A3 US 2005017732 W US2005017732 W US 2005017732W WO 2005112999 A3 WO2005112999 A3 WO 2005112999A3
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
agents
inhibitors
cancer treatment
collagen synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/017732
Other languages
English (en)
Other versions
WO2005112999A2 (fr
Inventor
Paul M Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectramed Inc
Original Assignee
Vectramed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectramed Inc filed Critical Vectramed Inc
Publication of WO2005112999A2 publication Critical patent/WO2005112999A2/fr
Anticipated expiration legal-status Critical
Publication of WO2005112999A3 publication Critical patent/WO2005112999A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des procédés pour le traitement de tumeurs au moyen d'une combinaison d'agents anticollagène et d'agents anticancéreux. Dans certains modes de réalisation, un ou plusieurs des agents anticollagène et des agents anticancéreux peuvent se présenter sous forme de matrice polymère biocompatible. L'invention concerne également des promédicaments comprenant des conjugués d'agents anticollagène et d'agents anticancéreux. Les compositions et les procédés de l'invention peuvent s'avérer utiles pour le rétrécissement ou la réduction de la taille d'une tumeur par suppression des barrières de diffusion de médicament qui résultent souvent de la matrice extracellulaire collagène de tumeurs solides.
PCT/US2005/017732 2004-05-20 2005-05-20 Traitement du cancer au moyen d'inhibiteurs de synthese du collagene Ceased WO2005112999A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57261104P 2004-05-20 2004-05-20
US60/572,611 2004-05-20

Publications (2)

Publication Number Publication Date
WO2005112999A2 WO2005112999A2 (fr) 2005-12-01
WO2005112999A3 true WO2005112999A3 (fr) 2009-05-07

Family

ID=35428859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/017732 Ceased WO2005112999A2 (fr) 2004-05-20 2005-05-20 Traitement du cancer au moyen d'inhibiteurs de synthese du collagene

Country Status (1)

Country Link
WO (1) WO2005112999A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883190B2 (en) 2006-12-01 2014-11-11 Wake Forest University Health Sciences Urologic devices incorporating collagen inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485088A (en) * 1982-03-26 1984-11-27 Bio-Products, Inc. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485088A (en) * 1982-03-26 1984-11-27 Bio-Products, Inc. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies

Also Published As

Publication number Publication date
WO2005112999A2 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2004030627A3 (fr) Methodes et compositions synergetiques pour le traitement du cancer
WO2004087075A3 (fr) Compositions et methodes de traitement du cancer
LUC00011I2 (fr)
WO2007047291A3 (fr) Anticorps anti-glypicane 3
SI1742644T1 (sl) Terapevtski sestavek ki vsebuje vsaj en derivat pirolobenzodiazepina in fludarabin
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
WO2008076278A3 (fr) Procédés de traitements
NO20083287L (no) Medikament for behandling av tumorer, samt anvendelse derav
WO2007050784A3 (fr) Traitement a base de combinaisons de medicaments a rapport fixe pour le traitement de tumeurs solides
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
TW200722098A (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in pharmaceutical compositions for treating cancer
WO2005112999A3 (fr) Traitement du cancer au moyen d'inhibiteurs de synthese du collagene
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
WO2008039525A3 (fr) Procédés de traitement du cancer au moyen d'antagonistes de cadhérine combinés à des agents anticancéreux
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
PT1618116E (pt) Complexos de ruténio(ii) para o tratamento de tumores
AU2003293665A1 (en) Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy
WO2005107765A3 (fr) Procede de traitement cardiaque
WO2005023199A3 (fr) Methylation d'un promoteur de socs-3 dans un cancer
UA90658C2 (ru) Композиция антагониста vegf и антипролиферативного средства
HK1123212A (en) Fixed ratio drug combination treatments for solid tumors
CY1117088T1 (el) Ενωσεις ισοϊνδολινης για χρηση στην θεραπευτικη αγωγη καρκινου
WO2004022001A3 (fr) Compositions et methodes permettant d'inhiber la proliferation de cellules cancereuses de prostate humaine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase